Thymidine labelling index as prognostic factor in resected non-small cell lung cancer.
To assess the prognostic value of tumor proliferative activity, 89 patients with operable non-small cell lung cancer were studied. Tumor samples were obtained during surgery and cell kinetics were analyzed by the in vitro thymidine labelling index (TLI). The overall median TLI (2.9) was used to identify two subsets of patients with high and low proliferating tumors. In univariate analysis survival was significantly longer in patients with lower TLI (P = 0.047) and with stage I-II (P = 0.003) and T1-T2 tumors (P = 0.043). In multivariate analysis, stage was the most important prognostic parameter (P = 0.004). The risk of death for patients with TLI higher than 2.9 was increased (hazard ratio = 2.01, CI = 0.96-4.27).
Alama
A
A
Department of Pharmacology, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
Costantini
M
M
Repetto
L
L
Conte
P F
PF
Serrano
J
J
Nicolin
A
A
Barbieri
F
F
Ardizzoni
A
A
Bruzzi
P
P
D000328:Adult; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D004273:DNA, Neoplasm / Q000096:biosynthesis; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D013936:Thymidine / Q000378:metabolism*
D004273:DNA, Neoplasm; D013936:Thymidine